You are here

Treatment with a drug

Document

Retinal vascular occlusive disease - Treatment with a drug Factor

Last reviewed for CCPS 05 October 2006.

Investigative Documents

Claimant Report - Nonsteroidal Anti-Inflammatory Drugs (excluding Aspirin) [CR9266]

Medical Report - Treatment with NSAIDs (excluding Aspirin) [MR9345]

Preliminary questions [36282]

36394

there is some evidence that a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, may be a factor in the development of the condition under consideration.

36395 the veteran used a drug as specified in the reasonable hypothesis Statement of Principles before the clinical onset of the condition under consideration.

36396

the veteran's use of a drug as specified in the reasonable hypothesis Statement of Principles was materially contributed to by treatment of an injury or illness which is identifiable.

36751the veteran has established the causal connection between using a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, and VEA service for the clinical onset of retinal vascular occlusive disease.

36397the veteran has established the causal connection between using a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, and operational service for the clinical onset of retinal vascular occlusive disease.

or

36403the veteran has established the causal connection between treatment with a drug belonging to the selective cyclo-oxygenase 2 inhibitor class of drugs and eligible service for the clinical onset of retinal vascular occlusive disease.

Clinical onset and operational service [36397]

36399the identified illness or injury, for which the veteran used a drug belonging to the nonsteroidal anti-inflammatory class of drugs, excluding aspirin, is causally related to operational service.

Clinical onset and eligible service [36403]

36752

for treatment of the identified illness or injury, the veteran was treated with a drug belonging to the selective cyclo-oxygenase 2 inhibitor class of drugs for a period specified in the balance of probabilities Statement of Principles before the clinical onset of the condition under consideration.

36405the identified illness or injury, for which the veteran was treated with a drug belonging to the selective cyclo-oxygenase 2 inhibitor class of drugs, is causally related to eligible service.